Medicine-Hematology and Medical Oncology
Academic Department
Affiliation
Research
administers grant
- 2021 Early Career Investigator''s Award
- 2024 ROBERT A. WINN DIVERSITY IN CLINICAL TRIALS: CAREER DEVELOPMENT AWARD AGREEMENT
- A Phase Ib trial of tazemetostat plus mosuntezumab in untreated follicular lymphoma
- A Program for Metastatic Breast Cancer Research
- A bioengineered model of tumor vessel interactions in pancreatic cancer
- AIDS Malignancy Consortium (AMC)
- ATHNdataset Hereditary Antithrombin Deficiency (HAD) Pilot Project
- Addgene 796255
- Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
- Autoimmune Stem-like CD8 T cells in Type I Diabetes
- BRIDGE (Blood cancer Research Initiative Developing Greater Engagement) with Community Patients
- Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies
- BioPharma Alliance Agreement- Janssen Research & Development
- Biophysical roles of pre-metatstatic niche evolution on transport of circulating tumor cells
- Breast Cancer in Young Women-Thriving After a Diagnosis
- Bridging Gaps and Transforming CARE for Young Breast Cancer Survivors and those with Metastatic Disease
- Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV
- Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving Frontline Treatment at Cancer Centers Within the LEO Cohort
- Characterizing and targeting aberrant NOTCH1 signaling in Richter''s syndrome
- Characterizing the Role and Targeting of the histone methyltransferase Setd2 in Multiple Myeloma
- Characterizing the role of BCL10 somatic mutations in B cell lymphomas
- Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer.
- Comprehensive Assessment of Cancer Theranostics Response
- Core: Targeting Enhancer Dysfunction in Hematological Malignancy- Core B
- Correlative biomarkers to optimize breast cancer treatment and prevention strategies
- Define genetically/epigenetically modified targets in the immune niche of DLBCLs- Project 2
- Define the evolutionary trajectories of CLL undergoing Richter transformation through single-cell multi-omics
- Defining The Functional Impact Of Composite Mutations In Oncogene-Driven Urothelial Cancer Using Circulating-Tumor Dna And Single-Cell Sequencing
- Defining the Role of the Gut Virome in Allogeneic HCT
- Defining the epigenetic landscape and therapeutic vulnerabilities of Richter''s syndrome in CRISPR-based mouse models
- Defining the impact of Kras mutational heterogeneity on the tumor microenvironment in pancreatic cancer
- Determinants Of The Racial/Ethnic Disparity In MGUS Risk: An Epidemiologic Study In 4 Cohorts
- Development of a platform for high throughput drug screening on CTC-derived organoid in breast and colorectal cancer
- Directing Fate, Subtype Identity And Survival In Human Pluripotent-Derived Midbrain Dopamine Neurons
- Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
- Dysregulated mechanoimmunology of epigenetics-driven lymphomas
- Early detection blood test for universal breast cancer screening to improve early diagnosis for women of all social and ethnic backgrounds
- Early intervention for the prevention of blood cancer development.
- Elucidating Metabolic Pathways Regulating Germinal Center B Cells And Derived Lymphomas
- Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma
- Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma progression and transformation - Caitlin Gribbin
- Enhancing the Efficacy of Docetaxel in Prostate Cancer
- Epigenetic basis and therapeutic interdiction of FL progression
- Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
- Exploiting tumor metabolism to optimize T cell therapy
- Exploiting tumor metabolism to optimize T cell therapy
- Exploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistance
- First-in-Class Dual AR-V7/AR-fl Molecular Glue Degrader for Prostate Cancer Treatment
- Germline-somatic interactions as drivers and therapeutic targets in bladder cancer
- Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab
- How the immune system becomes malignant
- Identifying B cell developmental changes and therapeutic vulnerabilities of MGA-mutant Richter''s syndrome
- Immune Tolerance Network
- Immunogenomic determinants of ethnic disparities in clinical outcomes for urothelial cancer patients
- Immunologic Eradication of Myeloproliferative Neoplasm Stem Cells
- Immunomodulatory Ligand B7-1 Targets p75 Neurotrophin Receptor in Neurodegeneration
- Inhibiting EZH2 to Improve Immunotherapies in B-Cell Lymphomas
- Inhibiting EZH2 to improve CAR T immunotherapy in B-cell lymphomas
- Investigating the tumor metabolism-hypoxia-vasculature axis in the response of TNBC to immunotherapy
- Janssen Biopharma Agreement
- Liquid biopsy to decipher lobular breast cancer metastatic spread
- Lymph node-targeted multistage chemoimmunotherapy for lymphoma
- Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling in Human Lymphomas
- Measuring Myeloproliferative Neoplasms Stem and Progenitor Cell Clonal Fitness to predict disease outcome
- Metabolic and Inflammatory Response to a Whole Food Plant-Based Diet in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Phase II Randomized Study
- Molecular Mechanisms of eIF4E mediated transformation
- Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
- Mutational and Aging Risk Factors for Myelodysplastic Syndrome
- New Approaches to Breast Cancer Prevention
- Novel Approach to Improving Prostate Cancer Screening Among African American Men
- Oncogenic Impact of eIF4E-dependent RNA export in cancer
- Optimization Of Urinary DNA Deep Sequencing Tests To Enhance Clinical Staging Of Bladder Cancer Patients
- Optimization of strategies to improve NCI-sponsored clinical trial participation throughout the Weill Cornell Medicine - Meyer Cancer Center Sphere
- Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
- Precision epigenetic therapy for SETD2+/- B cell lymphomas
- Precision translation of therapeutic regimens for follicular lymphoma
- Preclinical Development of Trop2 Directed ImmunoPET Tracer for Prostate Cancer.
- Predicting risk of disease progression in polycythemia vera (PV): development and validation of a highly predictive dynamic model using machine learning and rich data from automated extraction of medical records and a novel informatics pipeline
- Preventing follicular lymphoma progression and transformation through precision therapy
- Preventing follicular lymphoma progression and transformation through precision therapy
- Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic Targeting
- RCA with Montage Bio, Inc.
- Research Collaboration Agreement- Treeline Biosciences, Inc.
- Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy.
- Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies
- Role of chromatin remodeling complex BAF in immunity and lymphoma
- Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
- Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
- SETD2 and H1 Project
- SPONSORED RESEARCH AGREEMENT
- SRA with BMS
- TOX-driven CD8 T cell differentiation and dysfunction in tumors
- Targeted Small Molecule Inhibitors for Inv(16) Leukemia
- Targeted Therapies
- Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer
- Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
- Targeting Enhancer Dysfunction in Hematological Malignancy- Project 5
- Targeting Epigenetic Circuits in B-Cell Lymphomas
- Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
- Targeting MPN and Progenitor Cells
- Targeting Unmet Needs For B-cell Lymphomas
- Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
- Targeting ecDNA to reverse therapy-resistance in urothelial cancer.
- Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL
- The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
- The National Cord Blood Network, National Chair
- The National Cord Blood Network, Participating Center
- The Role of SPEN as Tumor Suppressor in BN2 DLBCL
- The VALIDATE study
- The association of HER2 expression on circulating tumor cells with the response to cyclin-dependent kinase 4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer
- The role of SPEN and NOTCH2 mutations in pathogenesis of DLBCL.
- Therapeutic Targeting of SIRT3 for Aggressive and Refractory Lymphomas
- Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
- Tracking MPN Fitness to speed development of disease modifying agents for MPNs
- Tumor-metabolism-driven therapies to overcome TNBC immune resistance
- Uncovering MGA-driven epigenetic reprogramming in Richter''s syndrome
- Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
- Understanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopy
- Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma
- Winn CDA Contact for Dr. Rohit Jain